Eledon Pharmaceuticals, Inc. Common Stock (ELDN) Stock Price
ELDNStock
$3.47+31.15%52W
Market Cap$281.98M
P/E—
PEG Ratio—
Div yield—
Beta0.88
ELDN Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)51.13%
Price vs S&P 500 (4W)-2.76%
VGM Score49.91
ELDN Earnings Surprise History
Q2 25-0.13est. -0.23
Q3 25-0.21est. -0.25
Q4 25-0.10est. -0.20
Q1 26-0.33est. -0.23
Q2 26-0.27est. -0.15
ELDN Analyst Recommendations
May 2026
Jun 2026
Jul 2026
Aug 2026
4.23
4.25
4.25
4.25
Industry Peers — Pharmaceuticals(571)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
ELDNEledon Pharmaceuticals, Inc. Common Stock | — | — | C | $3.47 |
| LLYEli Lilly & Co. | D | B | B | $1233.66 |
| JNJJohnson & Johnson | D | C | B | $273.14 |
| ABBVABBVIE INC. | D | C | B | $265.79 |
| MRKMerck & Co., Inc. | D | C | A | $156.45 |
| NVSNovartis AG | C | C | C | $159.98 |
| AZNAstraZeneca PLC | C | B | C | $169.66 |
| NVONovo-Nordisk A/S | B | C | C | $48.66 |
| ABTAbbott Laboratories | C | C | B | $116.13 |
| PFEPfizer Inc. | C | D | C | $28.57 |
| VRTXVertex Pharmaceuticals Inc | D | C | B | $552.85 |
About Eledon Pharmaceuticals, Inc. Common Stock
Eledon Pharmaceuticals is a clinical-stage biotech company developing tegoprubart, an anti-CD40L antibody targeting a well-validated pathway with broad therapeutic potential. The company is pursuing applications across transplantation, autoimmune diseases, and ALS, addressing significant unmet medical needs in each indication.